Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096949 · ClinicalTrials.gov registry record · NA
Implementing Cabenuva in Arkansas HIV Programs
A NA study, sponsored by University of Arkansas.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT05096949: Clinical Trial NA study, sponsored by University of Arkansas.
NCT05096949 is a NA study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096949, a NA study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study seeks to address this gap by studying two Cabenuva delivery strategies conducted at six outpatient HIV clinics in Arkansas, a Southern state with a large population of rural, poor, and African-American residents. The two delivery strategies are clinic delivery and home delivery. In the clinic delivery study arm patients will receive Cabenuva injections at the clinic (50 patients), and in the home delivery study arm patients will receive the injections at home (50 patients). The study team will follow the patients in both study arms for 10 months. After 5 months, the patients will complete a treatment satisfaction survey, and after 10 months the study team will examine clinic records to assess their medication adherence. Secondary outcomes will include clinician perceptions of acceptability, feasibility, and appropriateness of Cabenuva delivery strategies. The study team will also collect qualitative data from patients and clinic employees to learn more in depth about their perceptions of Cabenuva, the delivery strategies, their implementation, and barriers and facilitators. Finally, the study team will estimate the costs associated with the two delivery strategies from the clinic and patient perspectives. The data from this study provide information on what delivery strategies for long acting HIV medications offer best results, how these strategies are perceived by patients and clinicians, and how costly and feasible the strategies are to implement in practice.
Primary Outcome
Medication adherence will be quantified as a binary variable, based on whether the patient received all scheduled injections as planned or not. (As of January 2022, Cabenuva is approved for monthly and every-2-month injection schedule, and the study does not dictate which schedule the participants follow.)
Interventions
- OTHER Home visit delivery strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
Why NCT05096949 stopped before completion
NCT05096949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Home visit delivery strategy is the first listed.
NCT05096949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05096949 about?
NCT05096949 is a clinical study titled "Implementing Cabenuva in Arkansas HIV Programs". This study seeks to address this gap by studying two Cabenuva delivery strategies conducted at six outpatient HIV clinics in Arkansas, a Southern state with a large population of rural, poor, and African-American residents. The two delivery strategies are clinic delivery and home delivery. In the cl...
What is the current status of trial NCT05096949?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2022-03-07. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05096949?
The interventions under investigation include: Home visit delivery strategy (OTHER).
Who is sponsoring clinical trial NCT05096949?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05096949's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI